English translation of content medically reviewed in Romanian by Dr. Claudiu Ruscu, intensive care physician (anaesthesia & intensive care)· Romanian text reviewed 20 September 2026
450RON
Consultation included if you go ahead · otherwise 200 RON
or message us on WhatsAppCertified doctors · Payment at the clinic
A complete antioxidant combination: glutathione for cellular protection and vitamin C for immune support.
Available at the clinic or at home in Bucharest & Ilfov. See all prices.

The indication is decided at the medical assessment, based on your history, test results and goals. The doctor tells you whether this protocol is right for you.
The full list of contraindications is discussed during the consultation.
Glutathione + vitamin C
The dose is adjusted individually, based on the medical consultation. Every substance is pharmaceutical grade, given intravenously for higher bioavailability.
We assess your health and decide whether this protocol is right for you.
You are seated comfortably. The IV cannula is placed and monitoring begins.
The infusion is given slowly, under medical monitoring, for optimal tolerability.
Afterwards, we check how you are feeling. You can leave straight away.
The combined drip usually takes 40-60 minutes, given slowly, under medical supervision.
That is decided at your consultation. Antioxidant protocols usually involve a series of sessions followed by maintenance — based on your assessment, not a fixed schedule.
Usually you won't feel anything in particular during the drip, apart from the small prick when the cannula goes in. Most people go back to their usual activities straight away. You are monitored throughout.
The contraindications include G6PD deficiency, oxalate kidney stones, severe kidney failure, pregnancy and breastfeeding, and allergies to any of the components. They are checked at the medical consultation beforehand.
450 RON, medical assessment included. Available at the clinic or at home in Bucharest and Ilfov, with transparent pricing.
English translation of answers medically reviewed in Romanian. They do not replace a consultation — indications and contraindications are decided individually, at the medical assessment.
The studies below support the statements on mechanism, pharmacokinetics and safety on this page. They do not support a guaranteed therapeutic outcome — each one is followed by its limitation.
[1] Forman HJ, Zhang H, Rinna A Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med. 2009.
narrative review · PMID 18796312
Limitation: A short narrative biochemistry review, the introduction to a themed issue. It describes the function of the glutathione the body produces, not the effect of glutathione given from outside. It does not discuss the liver specifically.
[2] Witschi A, Reddy S, Stofer B, et al. The systemic availability of oral glutathione. Eur J Clin Pharmacol. 1992.
case series · sample: 7 · PMID 1362956
Limitation: Only 7 volunteers and a single dose, followed for 4.5 hours. It did not test long-term daily use, which gave a different result in a 2015 randomised trial (Richie). Analytical methods from 1992.
[3] Richie JP Jr, Nichenametla S, Neidig W, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 2015.
randomised trial · sample: 54 · PMID 24791752
Limitation: The outcome is a marker (the glutathione level), not a clinical benefit. The participants were healthy adults, and the effect disappeared after a one-month break. The study does not compare with intravenous administration.
[4] Aebi S, Assereto R, Lauterburg BH High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. Eur J Clin Invest. 1991.
case series · sample: 10 · PMID 1907548
Limitation: A single, high dose (2 g/m², about 3.5 g, 3–6 times above Synerva's protocols), in 10 volunteers. Glutathione inside the cells was not measured, and the methods date from 1991.
[5] Hauser RA, Lyons KE, McClain T, et al. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord. 2009.
randomised trial · sample: 21 · PMID 19230029
Limitation: 21 patients with Parkinson's disease, not healthy people, treated for only 4 weeks. The group is too small to pick up rare allergic or anaphylactic reactions.
[6] Marrades RM, Roca J, Barberà JA, et al. Nebulized glutathione induces bronchoconstriction in patients with mild asthma. Am J Respir Crit Care Med. 1997.
randomised trial · sample: 8 · PMID 9279219
Limitation: The route is inhaled, not intravenous, so its relevance to the drip is indirect. Only 8 patients. It supports caution in asthma, not a reaction rate for IV administration.
[7] Sarkar R, Yadav V, Yadav T, et al. Glutathione as a skin-lightening agent and in melasma: a systematic review. Int J Dermatol. 2025.
systematic review · PMID 39444151
Limitation: The search covered only the last 10 years, and the included studies are small, half of them at high risk of bias. For the IV route there is a single study with 16 people per arm. Most of the data concern the oral and topical forms.
[8] Sonthalia S, Daulatabad D, Sarkar R Glutathione as a skin whitening agent: Facts, myths, evidence and controversies. Indian J Dermatol Venereol Leprol. 2016.
narrative review · PMID 27088927
Limitation: A narrative review, not a systematic one. For the FDA Philippines warning it is a secondary source: the number and date of the warning are not given in the abstract. Adverse effects are not quantified.
[9] Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004.
case series · sample: 17 · PMID 15068981
Limitation: Healthy hospitalised volunteers. Only doses of up to 1.25 g were measured; the values for higher doses, including 5 g, are estimated by a model, not measured. The study has no clinical outcome: it shows concentrations, not a benefit.
[10] Levine M, Conry-Cantilena C, Wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A. 1996.
case series · sample: 7 · PMID 8623000
Limitation: Only 7 young, healthy men, hospitalised for 4–6 months on a diet without vitamin C. The study is of the oral route. Tissue saturation at low doses also shows that, in a person without a deficiency, it has not been demonstrated what a high IV dose adds.
[11] Padayatty SJ, Sun AY, Chen Q, et al. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One. 2010.
observational study · sample: 9328 · PMID 20628650
Limitation: The data are self-reported by complementary medicine practitioners: 199 of 550 responded, with a risk of under-reporting. The average dose was 28 g, more than 5 times the 5 g protocol, and the real number of patients is uncertain.
[12] Juneja D, Jain R, Nasa P Vitamin C-induced Hemolysis: Meta-summary and Review of Literature. Indian J Crit Care Med. 2022.
case series · sample: 14 · PMID 35712748
Limitation: 14 case reports, so it is not possible to estimate how common haemolysis is. There is publication bias, and the doses and settings (including critically ill patients) vary widely. It shows that the risk exists, not how large it is at 5 g.
[13] Robitaille L, Mamer OA, Miller WH Jr, et al. Oxalic acid excretion after intravenous ascorbic acid administration. Metabolism. 2009.
case series · PMID 19154961
Limitation: A phase I study in cancer patients with normal kidney function, with doses 3 to 20 times above 5 g and urine collected for only 6 hours. It does not measure the risk in people with kidney disease, which is exactly the group for whom the page asks for caution.
[14] Hemilä H, Chalker E Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013.
meta-analysis · sample: 11306 · PMID 23440782
Limitation: All included studies used oral vitamin C: the intravenous route was not assessed. The 8% shorter duration with regular use qualifies the categorical wording “does not treat”. In people under extreme physical exertion, the risk of a cold was halved.
[15] EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) Vitamin C and contribution to the normal function of the immune system: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006. EFSA J. 2015.
narrative review · PMID 42169835
Limitation: It is a regulatory opinion on DIETARY intake (the wording “contributes to the normal function”), and the 2015 application concerned children aged 0–3. It says nothing about benefits of high intravenous doses in people without a deficiency.
Indications, studies and frequently asked questions: the complete guide to Glutathione + vitamin C.
We use necessary cookies and, only with your consent, analytics and marketing cookies.We use cookies to improve your experience on this site. Strictly necessary cookies are always on. You can also accept analytics and marketing cookies, or decline them. Details